share_log

Piper Sandler Maintains Overweight on Syros Pharmaceuticals, Lowers Price Target to $7

Benzinga ·  Oct 3, 2023 15:10

Piper Sandler analyst Edward Tenthoff maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and lowers the price target from $11 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment